Dr. Natalie Kravchenko-Balasha and her research fellows from the Hebrew University, have received scientific recognition of their important work into brain cancer research, specifically into glioblastoma (GBM), aimed at finding new strategies to prevent GBM tumor cells infiltration, in an article that was published in the prestigious Oncogenesis Journal from the Nature Publishing Group on February 5th, 2020.
In addition to her scientific research at the Hebrew University of Jerusalem, Dr. Kravchenko–Balasha serves as Chief Scientist of the Bio Group’s subsidiary MEDPNC. The company focuses on predicting efficient personalized drug combinations for the treatment of individual cancer patients, according to their altered protein network structure
Read the full article on Nature
